Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
1.640
+0.050 (3.14%)
At close: Apr 25, 2025, 4:00 PM
1.660
+0.020 (1.22%)
After-hours: Apr 25, 2025, 4:24 PM EDT
Evaxion Biotech Stock Forecast
EVAX's stock price has decreased by -92.06% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Evaxion Biotech stock have an average target of 10, with a low estimate of 6.00 and a high estimate of 14. The average target predicts an increase of 509.76% from the current stock price of 1.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evaxion Biotech stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +753.66% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +753.66% | Feb 20, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $6 | Strong Buy | Maintains | $35 → $6 | +265.85% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +753.66% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $140 | Strong Buy | Reiterates | $140 | +8,436.59% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
6.77M
from 3.34M
Increased by 102.45%
Revenue Next Year
13.56M
from 6.77M
Increased by 100.30%
EPS This Year
-2.99
from -9.85
EPS Next Year
-2.81
from -2.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.9M | 27.9M | 28.0M | ||
| Avg | 6.8M | 13.6M | 27.2M | ||
| Low | n/a | n/a | 26.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 316.8% | 311.8% | 106.5% | ||
| Avg | 102.5% | 100.3% | 100.6% | ||
| Low | - | - | 92.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.92 | -2.89 | 0.05 | ||
| Avg | -2.99 | -2.81 | 0.05 | ||
| Low | -3.02 | -2.70 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.